Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 01/31/2025

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

AlphaCentric LifeSci Healthcare Fund

LYFCX | Fund

$12.99

$104 M

0.10%

$0.01

2.66%

Vitals

YTD Return

5.6%

1 yr return

9.1%

3 Yr Avg Return

4.2%

5 Yr Avg Return

9.2%

Net Assets

$104 M

Holdings in Top 10

37.7%

52 WEEK LOW AND HIGH

$13.0
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 2.66%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A

Min Investment

Standard (Taxable)

$2,500

IRA

$2,500

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 01/31/2025

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

AlphaCentric LifeSci Healthcare Fund

LYFCX | Fund

$12.99

$104 M

0.10%

$0.01

2.66%

LYFCX - Profile

Distributions

  • YTD Total Return 5.6%
  • 3 Yr Annualized Total Return 4.2%
  • 5 Yr Annualized Total Return 9.2%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -2.21%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency None

Fund Details

  • Legal Name
    AlphaCentric LifeSci Healthcare Fund
  • Fund Family Name
    Mutual Fund Series Trust
  • Inception Date
    Nov 29, 2019
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Mark Charest

Fund Description

p id="xdx_A8C_err--StrategyNarrativeTextBlock_zEinqhTw0Q67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund seeks to achieve its investment objective by investing in the life sciences and healthcare related companies that the Fund’s investment sub-advisor, LifeSci Fund Management LLC (the “Sub-Advisor”), believes to have potential to appreciate in value. Under normal market conditions, the Fund invests at least 80% of its net assets plus borrowings for investment purposes in the securities of companies in the life sciences and healthcare sectorsi, /iwhich the Fund defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a person’s or animal’s healthi. /iThe Fund invests in equity securities, primarily common stock, of these companies and may also invest, from time to time, in exchange traded funds (“ETFs”) that primarily invest in these companies. The Fund defines life sciences and healthcare companies to include those companies that are expected to derive 50% or more of their revenue from life sciences and healthcare related products and services. These companies may include development stage companies, which are entities span style="background-color: white"devoting substantially all of their efforts establishing a business for which commercial operations have not commenced or no significant revenue is being generated/span./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund may invest up to 15% of the Fund’s net assets in private and other companies whose securities may have legal or contractual restrictions on resale or are otherwise illiquid such as initial public offerings (“IPOs”), mezzanine financing offerings and other structured transactions. The Fund may invest in securities of companies of any market capitalization and in foreign companies either directly or through American Depositary Receipts (“ADRs”)./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund concentrates its investments (i.e., invests more than 25% of its assets) in the biotech and pharmaceutical; health care facilities and services; and medical equipment and devices industries, collectively. Each of these industries are commonly categorized within the healthcare sector because they share similar distribution channels and regulatory constraints./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"For hedging purposes or when the Sub-Advisor anticipates significant price changes due to company or market moving events, the Fund may also invest in inverse ETFs and purchase and sell call and put options on equity securities of life sciences and healthcare companies./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Sub-Advisor begins the investment selection process by systematically screening the universe of life sciences and healthcare companies using fundamental scientific and medical literature review, and input from leading scientific and medical experts to identify highly innovative thematic areas of interest. Financial analysis, market projections and corporate diligence are then performed to select the Fund’s investments./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"The Fund actively trades its portfolio investments, which may lead to higher transaction costs that may affect the Fund’s performance./span/p p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"span style="font-family: Times New Roman, Times, Serif; font-size: 10pt" /span/p
Read More

LYFCX - Performance

Return Ranking - Trailing

Period LYFCX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.6% -3.9% 14.0% 56.69%
1 Yr 9.1% -15.3% 23.7% 17.20%
3 Yr 4.2%* -17.3% 14.0% 51.32%
5 Yr 9.2%* -9.1% 11.5% 10.07%
10 Yr N/A* -1.6% 13.3% N/A

* Annualized

Return Ranking - Calendar

Period LYFCX Return Category Return Low Category Return High Rank in Category (%)
2024 -2.3% -28.2% 19.2% 52.87%
2023 3.3% -12.6% 19.0% 44.59%
2022 -6.2% -53.9% 3.2% 14.47%
2021 -15.0% -39.6% 24.2% 78.29%
2020 50.8% -13.6% 178.2% 6.04%

Total Return Ranking - Trailing

Period LYFCX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.6% -3.9% 14.0% 56.69%
1 Yr 9.1% -15.3% 23.7% 17.20%
3 Yr 4.2%* -17.3% 14.0% 51.32%
5 Yr 9.2%* -9.1% 11.5% 10.07%
10 Yr N/A* -1.6% 13.3% N/A

* Annualized

Total Return Ranking - Calendar

Period LYFCX Return Category Return Low Category Return High Rank in Category (%)
2024 -1.2% -28.2% 19.2% 82.80%
2023 6.1% -12.6% 19.0% 31.21%
2022 -1.8% -53.9% 3.7% 10.53%
2021 -4.3% -33.9% 26.0% 86.84%
2020 54.3% -0.7% 180.6% 4.70%

NAV & Total Return History

LYFCX - Holdings

Concentration Analysis

LYFCX Category Low Category High LYFCX % Rank
Net Assets 104 M 7.21 M 45.7 B 77.07%
Number of Holdings 68 25 430 67.52%
Net Assets in Top 10 31.2 M 2.55 M 23.9 B 80.25%
Weighting of Top 10 37.66% 18.5% 78.1% 82.80%

Top 10 Holdings

  1. FIRST AM-TR OB-X 8.83%
  2. HARMONY BIOSCIE 4.68%
  3. GALAPAGOS NV-ADR 3.77%
  4. MERCK CO 3.29%
  5. NEUROCRINE BIOSC 3.13%
  6. ARGENX SE - ADR 2.94%
  7. INDIVIOR PLC 2.85%
  8. BIOMARIN PHARMAC 2.76%
  9. SAREPTA THERAPEU 2.71%
  10. DYNAVAX TECHNOLO 2.71%

Asset Allocation

Weighting Return Low Return High LYFCX % Rank
Stocks 		89.92% 89.92% 106.13% 100.00%
Cash 		10.08% 0.00% 33.01% 5.73%
Preferred Stocks 		0.00% 0.00% 7.86% 54.78%
Other 		0.00% -22.99% 23.24% 56.69%
Convertible Bonds 		0.00% 0.00% 0.37% 37.50%
Bonds 		0.00% 0.00% 12.39% 53.50%

Stock Sector Breakdown

Weighting Return Low Return High LYFCX % Rank
Healthcare 		100.00% 59.26% 100.00% 21.05%
Utilities 		0.00% 0.00% 0.00% 33.55%
Technology 		0.00% 0.00% 22.69% 37.50%
Real Estate 		0.00% 0.00% 5.89% 36.18%
Industrials 		0.00% 0.00% 7.02% 37.50%
Financial Services 		0.00% 0.00% 1.60% 53.29%
Energy 		0.00% 0.00% 0.00% 33.55%
Communication Services 		0.00% 0.00% 9.11% 36.84%
Consumer Defense 		0.00% 0.00% 25.73% 41.45%
Consumer Cyclical 		0.00% 0.00% 1.92% 36.18%
Basic Materials 		0.00% 0.00% 7.16% 60.53%

Stock Geographic Breakdown

Weighting Return Low Return High LYFCX % Rank
US 		89.92% 68.81% 104.41% 68.15%
Non US 		0.00% 0.00% 28.83% 78.98%

LYFCX - Expenses

Operational Fees

LYFCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 2.66% 0.08% 50.00% 11.46%
Management Fee 1.25% 0.03% 50.00% 97.45%
12b-1 Fee 1.00% 0.00% 1.00% 80.52%
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

LYFCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

LYFCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

LYFCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 1.00% 238.00% 96.91%

LYFCX - Distributions

Dividend Yield Analysis

LYFCX Category Low Category High LYFCX % Rank
Dividend Yield 0.10% 0.00% 6.24% 12.10%

Dividend Distribution Analysis

LYFCX Category Low Category High Category Mod
Dividend Distribution Frequency None Annual Quarterly Annual

Net Income Ratio Analysis

LYFCX Category Low Category High LYFCX % Rank
Net Income Ratio -2.21% -2.54% 1.85% 98.67%

Capital Gain Distribution Analysis

LYFCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually

Distributions History

View More +

LYFCX - Fund Manager Analysis

Managers

Mark Charest

Start Date

Tenure

Tenure Rank

Nov 29, 2019

2.5

2.5%

Dr. Charest has served as a portfolio manager of LifeSci Fund Management since 2019. In 2017, he founded Phenomic Capital LLC to provide investment advice and consulting services focused on the healthcare sector. In 2019 Phenomic Capital became an affiliated majority owner of the LifeSci Fund Management. From 2015 to 2016, Mark was SVP at Tekla Capital Management, focused on public and private healthcare technology investments. Between 2012 and 2015, he was Portfolio Manager at New Leaf Venture Partners, focused on public healthcare technology investments. From 2010 to 2012, Dr. Charest was a Kauffman Fellow at Panorama Capital where he served on the board of directors of Itero Biopharmaceuticals and was a board observer at Presidio Pharmaceuticals and PowerVision. Dr. Charest is an inventor on eight drug patents. Prior to his investment career, he held an operating role in the oncology area as a Medicinal Chemistry Lab Manager at the Novartis Institutes for BioMedical Research. Dr. Charest earned his PhD in chemistry and chemical biology from Harvard University as a National Science Foundation Graduate Research Fellow, his MS in chemistry and chemical biology from Harvard University, and his BA in chemistry, with Highest Honors, from Rutgers University.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 8.04 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.